Moderna’s CEO told Bloomberg TV the company will scale back investments in late‑stage infectious‑disease vaccine trials amid mounting public and political backlash in the United States. The executive framed the move as a strategic redeployment of resources given current political headwinds and market sentiment. The shift reflects increasing sensitivity to vaccine policy debates and could reshape industry appetite for large, late‑stage vaccine investments.